Ascendis Pharma A (ASND) Return on Capital Employed (2015 - 2026)

Ascendis Pharma A has disclosed Return on Capital Employed across 12 years of filings, most recently posting 1.07% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 1.07%, down 3128135.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.07% (down 3128135.0% YoY), and the FY2025 annual result was 13.29%, up 903.0% from the prior year.
• Return on Capital Employed came in at 1.07% for Q1 2026 at Ascendis Pharma A, up from 77.11% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 353792.71% in Q2 2025 to a low of 3250.34% in Q1 2024.
• The 5-year median for Return on Capital Employed is 47.24% (2022), against an average of 41538.82%.
• Across the five-year window, Return on Capital Employed jumped 35323588 bps in 2025 and tumbled 3128135 bps in 2026, its largest moves.
• Ascendis Pharma A's Return on Capital Employed stood at 57.78% in 2022, then plunged by 572 bps to 388.46% in 2023, then soared by 7159 bps to 27420.7% in 2024, then plunged by 100 bps to 77.11% in 2025, then soared by 99 bps to 1.07% in 2026.
• The last three Return on Capital Employed figures came in at 1.07% (Q1 2026), 77.11% (Q4 2025), and 297625.78% (Q3 2025), per Business Quant data.